Core Insights - Evolent Health reported quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.10 per share, but showing an improvement from $0.04 per share a year ago [1] - The company experienced an earnings surprise of -50.00% and has not surpassed consensus EPS estimates in the last four quarters [2] - Evolent Health's revenues for the quarter were $479.53 million, exceeding the Zacks Consensus Estimate by 2.81%, but down from $621.4 million year-over-year [3] Financial Performance - The earnings report indicates a significant decline in stock performance, with shares down approximately 43.6% year-to-date compared to a 15.6% gain in the S&P 500 [4] - The current consensus EPS estimate for the upcoming quarter is $0.11 on revenues of $471.15 million, and for the current fiscal year, it is $0.18 on revenues of $1.87 billion [8] Industry Context - Evolent Health operates within the Zacks Medical Info Systems industry, which is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable industry outlook [9] - The company has a Zacks Rank of 4 (Sell), indicating expectations of underperformance in the near future based on unfavorable estimate revisions [7]